Viatris Inc: Fast-Acting Meloxicam Development, A $650M Buyback Blitz, & Other Key Developments!

Viatris, formerly known by the ticker VTRS, reported its Q1 2025 earnings, reflecting a careful balance of opportunities and challenges. For this quarter, Viatris recorded $3.3 billion in total revenues, representing a marginal decline of 2% when adjusted for divestitures and operational changes. This decline was largely attributed to continued issues at the Indore facility, which impacted revenues by approximately $140 million. Despite this setback, Viatris showed revenue growth in certain regions, notably in Europe and China, reflecting the company’s diversified market presence.